# In the UNITED STATES PATENT and TRADEMARK OFFICE

APPLICANT: Abbruzzese, et al.

SERIAL NO.: Not yet assigned

FILING DATE: February 23, 2004

TITLE: METHOD FOR THE PREVENTION AND TREATMENT OF CACHEXIA

**AND ANOREXIA** 

EXAMINER: ART UNIT: Chang, Celia

1625

**DOCKET NO.: 5863.US.C3** 

I certify that this correspondence (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail addressed to the Commissioner for Patents, Alexandria, VA 22313 on the

date shown below.

Wendy Detwier

- <u>23-04</u> Date

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

#### **INFORMATION DISCLOSURE STATEMENT**

#### Dear Sir:

In accordance with their duty of disclosure under 37 C.F.R. §1.56, and as authorized and encouraged under 37 C.F.R. §§ 1.97-1.98 and the provisions of MPEP §§ 609 and 707.05(b), Applicants submit herewith certain patent documents, publications and/or other information ("references") which the Patent and Trademark Office may wish to consider in examining the above-identified patent application. The identification of any reference herein is not intended to be and should not be understood as being an admission that such reference necessarily constitutes "prior art" within the meaning of applicable law.

The cited references are listed on attached form PTO-1449.

- A copy of each cited reference is provided;
- Copies of cited references are not provided because each has previously been made of record in the parent application, or is otherwise known to be in the Examiner's possession.

The Examiner is requested to review and evaluate each cited reference to make an independent assessment of the materiality of each, if any, to the examination of the above-identified application. The Examiner is requested to ignore any underscoring or highlighting which may have been done because such markings may or may not have any relationship to the subject matter of the present invention. The copies being submitted with this Statement are the best copies available at this time. Applicants respectfully request that (1) the references cited herein be made of record; (2) that the Examiner acknowledge his consideration of each reference by initialing and returning the enclosed copy of the PTO-1449 form; and (3) that such references appear on the printed patent as having been considered on the record.

With regard to payment of a fee:

No fee is due because:

This Statement is mailed within three months of the filing date of this application, or before the mailing date of a first office action on the merits (see 37 C.F.R. §1.97(b)).

Applicants certify that each reference cited in this Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement. (see 37 C.F.R. §1.97(e)).

This Statement is filed after the mailing date of a first Office Action on the merits but before the mailing date of either a final action or a Notice of Allowance (see 37 C.F.R. §1.97(c)) so a fee of \$180.00 is specified by 37 C.F.R. §1.17(p).

If any fees are owed, or any credit is due pertaining to this case, please charge that fee or apply that credit to Deposit Account No. 01-0025. A duplicate sheet of this page is enclosed.

Ross Products Division of ABBOTT LABORATORIES Dept. 108140-DS/1 625 Cleveland Avenue Columbus, OHIO 43215-1724

Telephone: (614) 624-3012 Facsimile: (614) 624-3074

Docket: 5863.US.C3

Respectfully submitted,

by Nickki L. Parlet Reg. No. 44,996

			ИFNTS	

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date (if appro.)
	5,053,387	10/1991	Alexander			
	5,326,569	07/1994	Acosta			
	5,599,835	02/1997	Fischer			
	5,776,913	07/1998	Ogilvie			
	5,223,285		DeMichele, et			
			al.			
	5,444,054		Garleb, et al.			
	5,431,925		Ohmori, et al.			
	5,385,740		Tisdale, et al.	Ī		
	5,308,832		Garleb, et al.	Ī		
	5,393,784		Richarson			

## **FOREIGN PATENT DOCUMENTS**

Document Number	Date	Name	Class	Subclass	Translation (Yes No)
WO 97/13415 A	04/17/97	Colgate Palmolive			
EP 0367724 A	05/09/90	Sandoz AG			
EP 0756827 A	02/05/96	Braun Melsungen			
WO 95/08349 A	03/30/95	Flockhart, I.			
EP 0462398 A	12/27/91	Hoffmann La			
		Roche			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Blot, et al., "Nutrition Intervention Trials in Linxian, China: Supplementation With Specific Vitamin/Mineral Combinations, Cancer Incidence, and Disease-Specific Mortality in the General Population", Journal of the National Cancer Institute, Vol. 85, No. 18, September 15, 1993
	Li, et al., "Nutrition Intervention Trials in Linxian, China: Multiple Vitamin/Mineral Supplementation, Cancer Incidence, and Disease-Specific Mortality Among Adults With Esophageal Dysplasia", Journal of the National Cancer Institute, Vol. 85, No. 18, September 15, 1993
	Abstract of Japanese Patent Application Number 5-335311
	Abstract of Japanese Patent Application Number 6-51064
	Abstract of Japanese Patent Application Number 1-282844
	DeRham, "Nitrogen content of proteins" CA 97:143230 (1982)
	Shellock, et al., "Brown adipose tissue in cancer patients" MEDLINE 86140335 (1986)
	DeMichele, et al., "Enhanced skeletal muscle and" MEDLINE 88301889 (1988)
	Gollaher, et al., "The effect of increasing levels of fish oil" MEDLINE 93280824 (1993)
EXAMINE	<u> </u>

**Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Initial	Document Number	Date	Name	Class	Subdass	Filing Date (if appro.)			
·	5,457,130	10/1995	Tisdale						
FC	FOREIGN PATENT DOCUMENTS								

Document Number Date Name Class Subclass Translation (Yes No)

· · · · · ·   · · · · · · · · · · · ·					
OTHER POOLING A	A Alex Title D.4. D.4. a D				
	Author, Title, Date, Pertinent Pages, Etc.)				
	., et al., Effect of Fish Oil on the Fatty Acid Composition of Human and Infant Erythroytes, LIPIDS, Vol. 27, No. 11 (1992), pp. 863-869				
Tisdale, Michael J., e	et al., Inhibition of Weight Loss by ω-3 Fatty Acids in an Experimental NCER RESEARCH 50, 5022-5026, August 15, 1990				
	., et al., Interleukin-1, Anorexia, and Dietary Fatty Acids, ANNALS OF				
THE NEW YORK AC	CADEMY OF SCIENCES, Vol. 587, pp. 332-338				
California, 90080-00					
(GenSect) 1990, 81:					
Pathogenic Mechani 7 No. 5, September/					
	O., Supportive Nutrition to Prevent Cachexia and Improve Quality of ONCOLOGY, Vol. 22, No. 2, Supplement 3 (April), 1995, pp. 98-111				
NUTRITION, Vol. 12	, et al., Cancer Cachexia, JOURNAL OF PARENTAL AND ENTERAL , No. 3, pp. 286-294 (1988)				
	Ph.D., et al., Hormonal and Metabolic Abornalities in the Praction, JOURNAL OF				
	ENTERAL NUTRITION, Vol. 16, No. 6, Supplement, pp. 60S-64S				
	J., M.D., et al. Cytokines and Their Role in the Pathophysiology of DURNAL OF PARENTERAL AND ENTERAL NUTRITION, Vol. 16, pp. 50S-55S (1992)				
Tisdale, M.J., Cance	er Cachexia, ANTI CANCER DRUGS, Vol. 4, pp. 113-125 (1993)				
	M.D., Effects of Artificial Nutrition on the Nutritional Status of Cancer OF PARENTERAL AND ENTERAL NUTRITION, Vol. 13, No. 4 pp.				
Derwent – 01104374					
Derwent – 01104374					
Derwent – 00840560					
February 22, 1996, p					
Wigmore, Stephen, e Cachexia in Patients S30	et al., The Effect of Polyunsaturated Fatty Acids on the Progress of With Pancreatic Cancer, NUTRITION, Vol. 12, No. 1, 1996, pp. S27-				
	tates Patent No. 5,393,784				
EXAMINER:	DATE CONSIDERED:				

**Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			eer <u> </u>
FORM PTO-1449 (Rev. 2032)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.: 5863.US.C3	Serial No. : Not yet assigned
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant Abbruzzese, et al.	
	(Use several sheets if necessary)	Filing Date: Feb. 23, 2004	Group: 1625

# **U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subdass	Filing Date (if appro.)
	_					

## **FOREIGN PATENT DOCUMENTS**

Document Number	Date	Name	Class	Subclass	Translation (Yes No)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Keller, Ulrich, Pathophysiology of cancer cachexia, Supportive Care in Cancer (1993) 1:209-294
	Derwent – 90-225190
	Derwent – Abstract 010905121
	Ottery, Faith D., M.D. Cancer Cachexia, CANCER PRACTICE, March/April 1994, Vol. 2, No. 2, pp. 123-131
	Rossi-Fanelli, Filippo, et al., Plasma Tryptophan and Anorexia in Human Cancer, EUR J CANCER CLIN ONCOL, Vol. 22, No. 1 pp. 89-95, 1986
	Krause, Rudolf, et al., Brain Tryptophan and the Neoplastic Anorexia-Cachexia Syndrome, CANCER, September 1979, 44: pp. 1003-1008
	Meguid, Michael, et al., The Early Cancer Anorexia Paradigm: Changes in Plasma Free Tryptophan and Feeding Indexes, JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, Vol. 16, No. 6, Supplement, pp. 56S-59S
	Abstract of DE 39010048
	Derwent 008338139
	Impact® with Fiber (1992 Clinical Products Division, Sandoz Nutrition Corporation)
	Impact® (June 1995 Ross Products Division, Abbott Laboratories)
	Impact® with Fiber (1992 product sheet)
EXAMINE	R: DATE CONSIDERED:

**Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

										neet <u>1</u> of <u>1</u>
FORM PTO-	S. Department		Atty. Docket I 5863.US.C3	No.:	Serial No.					
(Rev. 2032)	(Rev. 2032) Patent and Trademark Office									Not yet assigned
	INFORMATION DISCLOSURE									assigned
		STATEME						<mark>Applicant</mark> Abbruzzese, et a	al.	
		(Use severa	l sheets	if necess	sary)			Filing Date:		Group:
								Feb. 23, 200	4	1625
Examiner U.S	Document I	DOCUMENT			I Manage			10.		
Initial	Document	vumber	Date		Name	Cla	ass	Subdass	Filing Da	ate (if appro.)
	-									
					<u> </u>			1	l	
							-	<del></del>	-	
-						<del></del>		<del>                                     </del>		
<del></del>	<del>                                     </del>							<del>                                     </del>		
								-		
								<del> </del>		
FA	DEICH DA	TENT DOCUI	MENTO					<u> </u>		
	Documen		Da		Name	Clas		Subclass	Topole	tion (Von No)
	EP 0 642		Da	le	Name	- Clas	55	Subclass	Transia	ation (Yes No)
_	EP 0 042	/91			ļ					
								<del> </del>		
OT	HER DOCL	JMENTS (Inc	luding	Author.	Title, Date, P	ertinent Pac	aes.	Etc.)	L	
									ents bet	fore and after
	Si	urgical Tumo	or Ablai	tion". Al	NTICANCER	RESEARC	CH 14	4: 1451-1456	(1994)	ioro and artor
		<u> </u>		,					1.55.7	
	<del>                                     </del>				***					
	<del>                                     </del>	<del> </del>								
	+-+									
	+ +									
	+									
	XAMINER:				DATE CON	ICIDEDED:				
E.	ANIINEK.				DATE CON	ISIDERED.				

**Examiner:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.